Covance Appoints Dr. Barry J. Goldstein to Lead Expanded Cardiovascular, Metabolic, Endocrine, and Renal Therapeutic Area




Princeton, N.J., January 21, 2014 - Covance today announced that Barry J. Goldstein, M.D., Ph.D., has joined its Clinical Development Services business as Vice President and Global Therapeutic Area Head of the expanded Cardiovascular, Metabolic, Endocrine and Renal unit.  In this new role, Dr. Goldstein will join the Medical & Scientific Affairs leadership team and will be based in Princeton, N.J.

"Barry brings significant endocrinology, metabolism and broad drug development experience to complement our existing cardiovascular expertise at Covance," said Ken Somberg, Chief Medical Officer and Vice President, Clinical Development Services.  "Barry is a noted leader in the field of diabetes mellitus and endocrinology.  His leadership will help us expand our strategic vision in these key therapeutic areas, as well as provide critical scientific insight to our colleagues and our clients throughout the biopharmaceutical industry."

Covance's cardiovascular/metabolic therapeutic area has grown significantly in recent years as a result of its successful approaches in cutting-edge lipid trials and large cardiovascular outcomes studies.  In addition, the group has expanded its capabilities and ongoing activities in the metabolic and endocrine areas, particularly in diabetes mellitus-related clinical trials.

Dr. Goldstein joins Covance from Merck where, since 2008, he served as Vice President in Clinical Research and Therapeutic Area Head for Diabetes and Endocrinology.  In this role, he managed Merck's Phase II-IV clinical development team for a large portfolio including diabetes, obesity, osteoporosis, and women's health.  His responsibilities included strategic input to proof-of-concept study designs, clinical trial strategies, protocol development, regulatory filings, responses to payer inquiries, lifecycle management activities, as well as pharmacovigilance and post-marketing studies.

"Covance has an excellent reputation as a preferred partner to the pharmaceutical industry," said Dr. Goldstein.  "I'm looking forward to working closely with such a talented and experienced team within the clinical development organization, as well as the global medical and scientific community across the company."

In addition to his biopharmaceutical industry experience, Dr. Goldstein's extensive research, academic and medical career includes serving as Director, Division of Endocrinology, Diabetes & Metabolic Diseases, Jefferson Medical College at Thomas Jefferson University in Philadelphia from 1992 to 2008.  His most recent academic roles include Professor of Medicine, Biochemistry and Molecular Pharmacology at Jefferson from 1997-2008. 

Dr. Goldstein is a Fellow of the American College of Endocrinology (FACE).  He earned his Ph.D. in biochemistry and M.D. with Honor from the University of Rochester School of Medicine and a Bachelor of Science with Distinction from Cornell University.  For clinical and research training in diabetes and endocrinology, he studied at the Joslin Diabetes Center and Harvard Medical School in Boston.

About Covance Inc.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2.2 billion and more than 12,000 employees located in over 60 countries.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

###



distributed by